Replies to post #18970 on Cytogenix (fka CYGX)

[hogger]

Paulness, I do not need to buy in ... I have sufficient holdings in CYGX and intend to maintain that position. If you want to stay focused, then I submit that you should proivide some hard facts that justify this major dilution that will benefit on a select few.

There have simply not been enough SUCCESSES to justify giving management millions of dollars of additional compensation.

[Chadman]

I read in the filing that one of the main reasons for this is to use these options to attract the best and the brightest in the future. I am looking at page 18 of the filing which highlights (I assume) where these options are designed to be assigned. I see that 20,200,000 of the options are slated to go to:

Malcolm H. Skolnick - 3,000,000
Lawrence Wunderlich - 3,000,000
All executive officers as a group - 10,200,000
All current directors who are not executive officers as a group - 1,000,000.
All employees, including all current officers who are not executive officers, as a group - 3,000,000.

These are all current employees, officers, management and directors. I have not studied this filing in earnest, nor do I pretend to be able to understand all of it even if I did. But where does it show any of the options to be held in reserve to attract the best and brightest in the future? It's probably there, but unless I'm way off base I don't see where the options are going to anyone except current folks...who not surprisingly would be all for this.

Would love some comments on this. Again, just a quick take on my part and I hope I am off base.